Compare Mattel Inc (MAT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Novo Nordisk A/S — how do they compare? Mattel Inc trades at $16.7 (market cap $4.74B), while Novo Nordisk A/S trades at $38.12 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 34.9× Mattel Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Novo Nordisk A/S for 116 Days on average.
| MAT | NVO | |
|---|---|---|
Market Cap | $4.74B | $165.31B |
Volume | 11,809,722 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $63.98 |
52-Week Low | $12.66 | $35.29 |
Typical Hold Time | 97 Days | 116 Days |
Enterprise Value | $6.96B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.37, up 2.76% amid takeover speculation, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings but maintains solid profitability with a 7.78% net income margin and a reasonable P/E of 12.22. Recent news highlights CEO transition and acquisition interest from Authentic Brands Group, potentially valuing the firm around $6 billion.
The stock's outlook is supported by strong analyst sentiment (52.94% buy ratings) and a stable financial base, though risks include earnings volatility and leadership changes. Near-term price action hinges on takeover developments and new CEO execution, with the consensus price target at $15.00 suggesting limited upside from current levels.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
